查看購物車
  • Simplified Chinese
  • English
2021-2031年歐洲胃腸藥物市場報告（範圍、細分、動態和競爭分析）
市場調查報告書
商品編碼
1819736

2021-2031年歐洲胃腸藥物市場報告（範圍、細分、動態和競爭分析）

Europe Gastrointestinal Drugs Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 165 Pages | 訂單完成後即時交付

價格

歐洲胃腸藥物市場預計將大幅成長，到 2031 年將達到約 342.9935 億美元，高於 2023 年的 196.5029 億美元。這一成長代表著 2023 年至 2031 年的年複合成長率(CAGR) 為 7.2%。

執行摘要和市場分析

歐洲胃腸道藥物市場主要分為幾個主要區域，包括德國、英國、法國、義大利、西班牙和歐洲其他地區。該市場的預期成長主要受發炎性腸道疾病 (IBD) 和腸躁症 (IBS) 等胃腸道疾病盛行率上升的推動。此外，研發活動也顯著增加，促進了針對各種胃腸道疾病的先進治療方案的研發。

市場區隔分析

對歐洲胃腸藥物市場的分析揭示了幾個重要的部分，包括藥物類別、應用、給藥途徑和配銷通路。

1. 藥品類別：市場分為生物製劑、止瀉藥和瀉藥、酸中和劑、抗發炎藥、止吐藥和止吐藥等。 2023年，生物製劑佔據了最大的市場。

2. 應用：市場根據應用細分，例如腸躁症、發炎性潰瘍性結腸炎、克隆氏症、胃腸炎、乳糜瀉等。腸躁症是2023年市場的最大貢獻者。

3. 給藥途徑：市場分為口服和非腸道給藥途徑。口服給藥在2023年佔據了更大的佔有率，這反映了患者的偏好和易用性。

4.配銷通路：分銷管道包括醫院藥房、零售藥房和線上藥房。 2023年，醫院藥房佔據了最大的市場佔有率，這表明醫療機構在配藥方面存在很大的依賴性。

市場展望

胃腸道疾病涵蓋一系列影響胃腸道的疾病，包括灼熱、發炎性腸道疾病 (IBD)、腸躁症 (IBS)、胃腸炎、胃食道逆流症 (GERD)、便秘和腹瀉等常見問題。這些疾病是常見的慢性發炎性疾病，影響全球相當一部分人口。導致胃腸道疾病發生率上升的因素包括久坐不動的生活方式、飲食習慣的改變以及壓力水平的增加。隨著人口老化，這些疾病的負擔預計將持續上升。

2023年7月發表的一項題為《胃食道逆流症》的最新研究強調，GERD是最常見的胃腸道疾病之一，影響約20%的人口。這種疾病不僅透過直接和間接成本造成巨大的經濟負擔，也嚴重影響個人的生活品質。

歐洲慢性消化系統疾病的發生率不斷上升，而人口老化和生活方式因素（包括肥胖率上升和高酒精消費）進一步加劇了這一趨勢。根據歐洲克隆氏症和潰瘍性結腸炎協會聯合會的數據，全球約有1,000萬人患有發炎性腸道疾病（IBD）。英國克隆氏症和結腸炎協會2022年的研究表明，英國每123人中就有1人被診斷出患有克隆氏症或潰瘍性結腸炎，總數約為50萬人。

此外，近幾十年來，腸躁症（IBS）的盛行率急劇上升。國際胃腸病基金會報告稱，IBS是最常見的功能性胃腸病，影響全球10%至15%的人口。哥德堡大學的一項研究發現，全球每十個成年人中就有四個患有不同程度的功能性胃腸病，美國每年約有240萬至350萬人次因IBS就診。胃腸疾病盛行率的上升推動了對有效治療的需求，從而推動了胃腸藥物市場的成長。

國家洞察

歐洲胃腸道藥物市場進一步按國家/地區進行分析，其中德國在2023年佔據市場佔有率的首位。由於胃腸道感染和疾病的發生率不斷上升，德國市場尤其具有吸引力。根據《德國醫學雜誌》（Deutsches Arzteblatt）2023年的一篇文章，發炎性腸道疾病（IBD）的盛行率正在迅速上升，影響了約0.7%的德國人口，約60萬名患者。此外，胃腸道感染每年在德國約造成2,450萬人次的門診就診。

各製藥公司不斷開發有效的治療方案，加之易患胃腸道疾病的老年人口不斷成長，預計將推動德國市場的成長。例如，2021年10月，Renexxion Ireland Ltd. 與 Dr. Falk Pharma GmbH 合作開發並商業化了用於治療胃輕癱的新型胃腸道促動力藥那羅那必利 (Naronapride)。德國是歐洲最大的醫藥市場，2021年的產值達380.3億美元，並在研發方面投入了大量資金，這進一步支持了該地區胃腸道藥物市場的成長。

公司簡介

歐洲胃腸藥物市場的主要參與者包括賽諾菲公司、葛蘭素史克公司、強生公司、博士倫健康公司、阿斯特捷利康公司、武田製藥有限公司、艾伯維公司、拜耳公司和輝瑞公司。這些公司正在採用各種策略，包括擴張、產品創新和併購，以增強其市場佔有率並為消費者提供創新解決方案。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第4章：歐洲胃腸藥物市場－主要市場動態

  • 市場促進因素
    • 胃腸道疾病病例增加
    • 生物製劑的不斷發展
  • 市場限制
    • 生物製劑成本高
    • 治療嚴重潰瘍性結腸炎或克隆氏症的生物製劑平均費用
  • 市場機會
    • 企業的策略舉措
  • 未來趨勢
    • 加大對新藥開發與人工智慧技術的研究投入
  • 促進因素和限制因素的影響：

第5章：歐洲胃腸藥物市場分析

  • 2021-2031年歐洲胃腸藥物市場收入

第6章：歐洲胃腸藥物市場分析－依藥物類別

  • 生物製劑
  • 止瀉藥和瀉藥
  • 酸中和劑
  • 抗發炎藥物
  • 止吐藥和止噁心藥
  • 其他

第7章：歐洲胃腸藥物市場分析-按應用

  • 急躁性腸症候群
  • 發炎性潰瘍性結腸炎
  • 克隆氏症
  • 胃腸炎
  • 乳糜瀉
  • 其他

第8章：歐洲胃腸藥物市場分析-按給藥途徑

  • 口服
  • 腸外

第9章：歐洲胃腸藥物市場分析-按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 10 章：歐洲胃腸藥物市場-國家分析

  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其餘

第 11 章：產業格局

  • 概述
  • 胃腸藥物市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 12 章：公司簡介

  • Sanofi SA
  • GSK Plc
  • Johnson & Johnson
  • Bausch Health Companies Inc
  • AstraZeneca Plc
  • Takeda Pharmaceutical Co Ltd
  • AbbVie Inc
  • Bayer AG
  • Pfizer Inc

第 13 章：附錄

Product Code: TIPRE00016280

The European gastrointestinal drugs market is projected to grow significantly, reaching approximately USD 34,299.35 million by 2031, up from USD 19,650.29 million in 2023. This growth represents a compound annual growth rate (CAGR) of 7.2% from 2023 to 2031.

Executive Summary and Market Analysis

The market for gastrointestinal drugs in Europe is divided into several key regions, including Germany, the UK, France, Italy, Spain, and the Rest of Europe. The anticipated growth in this market is primarily driven by the increasing prevalence of gastrointestinal disorders such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Additionally, there is a notable rise in research and development activities, which is fostering the creation of advanced therapeutic options for various gastrointestinal conditions.

Market Segmentation Analysis

The analysis of the European gastrointestinal drugs market reveals several important segments, including drug class, application, route of administration, and distribution channel.

1. Drug Class: The market is categorized into biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants, among others. In 2023, biologics accounted for the largest market share.

2. Application: The market is segmented based on applications such as irritable bowel syndrome, inflammatory ulcerative colitis, Crohn's disease, gastroenteritis, celiac disease, and others. The irritable bowel syndrome segment was the largest contributor to the market in 2023.

3. Route of Administration: The market is divided into oral and parenteral routes. The oral administration segment held a larger share in 2023, reflecting patient preferences and ease of use.

4. Distribution Channel: The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies represented the largest share of the market in 2023, indicating a strong reliance on healthcare facilities for dispensing these medications.

Market Outlook

Gastrointestinal diseases encompass a range of conditions affecting the gastrointestinal tract, including common issues like heartburn, IBD, IBS, gastroenteritis, gastroesophageal reflux disease (GERD), constipation, and diarrhea. These conditions are prevalent chronic inflammatory disorders that impact a significant portion of the global population. Factors contributing to the rise in gastrointestinal diseases include sedentary lifestyles, changing dietary habits, and increased stress levels. As the population ages, the burden of these diseases is expected to escalate.

A recent study titled "Gastroesophageal Reflux Disease," published in July 2023, highlighted that GERD is one of the most commonly diagnosed gastrointestinal conditions, affecting around 20% of the population. This condition not only imposes a substantial economic burden through direct and indirect costs but also significantly affects individuals' quality of life.

The increasing incidence of chronic digestive diseases in Europe is further exacerbated by an aging population and lifestyle factors, including rising obesity rates and high alcohol consumption. According to the European Federation of Crohn's & Ulcerative Colitis Associations, approximately 10 million individuals worldwide suffer from IBD. Research from Crohn's & Colitis UK in 2022 indicated that 1 in every 123 people in the UK is diagnosed with either Crohn's disease or ulcerative colitis, totaling around half a million individuals.

Moreover, the prevalence of IBS has surged in recent decades. The International Foundation for Gastrointestinal Disorders reports that IBS is the most common functional gastrointestinal disorder, affecting 10-15% of the global population. A study from the University of Gothenburg found that four out of ten adults worldwide experience varying degrees of functional gastrointestinal disorders, with the US seeing approximately 2.4 to 3.5 million hospital visits for IBS each year. This rising prevalence of gastrointestinal diseases is driving the demand for effective treatments, thereby propelling the growth of the gastrointestinal drugs market.

Country Insights

The European gastrointestinal drugs market is further analyzed by country, with Germany leading the market share in 2023. Germany's market is particularly attractive due to the increasing rates of gastrointestinal infections and disorders. According to a 2023 article from Deutsches Arzteblatt, the prevalence of IBD is rapidly rising, affecting about 0.7% of the German population, or approximately 600,000 patients. Additionally, gastrointestinal infections account for around 24.5 million outpatient visits annually in Germany.

The development of effective treatment options by various pharmaceutical companies, along with a growing elderly population susceptible to gastrointestinal issues, is expected to drive market growth in Germany. For instance, in October 2021, Renexxion Ireland Ltd. partnered with Dr. Falk Pharma GmbH to develop and commercialize Naronapride, a novel GI prokinetic for gastroparesis. Germany's status as Europe's largest pharmaceutical market, with a production volume of USD 38.03 billion in 2021 and a robust investment in research and development, further supports the growth of the gastrointestinal drugs market in the region.

Company Profiles

Key players in the European gastrointestinal drugs market include Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, and Pfizer Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Europe Gastrointestinal Drugs Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Cases of Gastrointestinal Diseases
    • 4.1.2 Increasing Development of Biologics
  • 4.2 Market Restraints
    • 4.2.1 High Cost of Biologics
    • 4.2.2 Average Cost of Biologic Drugs for Severe Ulcerative Colitis or Crohn's Disease
  • 4.3 Market Opportunities
    • 4.3.1 Strategic Initiatives by Companies
  • 4.4 Future Trends
    • 4.4.1 Increasing Research Investment for Novel Drug Development and Artificial Intelligence-Based Techniques
  • 4.5 Impact of Drivers and Restraints:

5. Gastrointestinal Drugs Market - Europe Analysis

  • 5.1 Europe Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031

6. Europe Gastrointestinal Drugs Market Analysis - by Drug Class

  • 6.1 Biologics
    • 6.1.1 Overview
    • 6.1.2 Biologics: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.2 Antidiarrheal and Laxatives
    • 6.2.1 Overview
    • 6.2.2 Antidiarrheal and Laxatives: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Acid Neutralizers
    • 6.3.1 Overview
    • 6.3.2 Acid Neutralizers: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Anti-inflammatory Drugs
    • 6.4.1 Overview
    • 6.4.2 Anti-inflammatory Drugs: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.5 Antiemetic and Antinauseants
    • 6.5.1 Overview
    • 6.5.2 Antiemetic and Antinauseants: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Gastrointestinal Drugs Market Analysis - by Application

  • 7.1 Irritable Bowel Syndrome
    • 7.1.1 Overview
    • 7.1.2 Irritable Bowel Syndrome: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Inflammatory Ulcerative Colitis
    • 7.2.1 Overview
    • 7.2.2 Inflammatory Ulcerative Colitis: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Crohn's Disease
    • 7.3.1 Overview
    • 7.3.2 Crohn's Disease: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Gastroenteritis
    • 7.4.1 Overview
    • 7.4.2 Gastroenteritis: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Celiac Disease
    • 7.5.1 Overview
    • 7.5.2 Celiac Disease: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Gastrointestinal Drugs Market Analysis - by Route Of Administration

  • 8.1 Oral
    • 8.1.1 Overview
    • 8.1.2 Oral: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Parenteral
    • 8.2.1 Overview
    • 8.2.2 Parenteral: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Gastrointestinal Drugs Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacies: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Retail Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacies: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Online Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Online Pharmacies: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. Europe Gastrointestinal Drugs Market - Country Analysis

  • 10.1 Europe
    • 10.1.1 Europe Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Germany: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.1.1 Germany: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.1.2 Germany: Europe Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.1.3 Germany: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.1.4 Germany: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.2 United Kingdom: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.1 United Kingdom: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.2.2 United Kingdom: Europe Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.2.3 United Kingdom: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.2.4 United Kingdom: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.3 France: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.1 France: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.3.2 France: Europe Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.3.3 France: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.3.4 France: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.4 Italy: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.1 Italy: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.4.2 Italy: Europe Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.4.3 Italy: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.4.4 Italy: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.5 Spain: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.5.1 Spain: Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.5.2 Spain: Europe Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.5.3 Spain: Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.5.4 Spain: Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 10.1.1.6 Rest of Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.6.1 Rest of Europe Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 10.1.1.6.2 Rest of Europe Gastrointestinal Drugs Market Breakdown, by Application
        • 10.1.1.6.3 Rest of Europe Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 10.1.1.6.4 Rest of Europe Gastrointestinal Drugs Market Breakdown, by Distribution Channel

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Gastrointestinal Drugs Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Sanofi SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 GSK Plc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Johnson & Johnson
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Bausch Health Companies Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 AstraZeneca Plc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Takeda Pharmaceutical Co Ltd
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AbbVie Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Bayer AG
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Pfizer Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Gastrointestinal Drugs Market Segmentation
  • Table 2. Germany: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 3. Germany: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 4. Germany: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 5. Germany: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 6. United Kingdom: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 7. United Kingdom: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 8. United Kingdom: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 9. United Kingdom: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 10. France: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 11. France: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 12. France: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 13. France: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 14. Italy: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 15. Italy: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 16. Italy: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 17. Italy: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 18. Spain: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 19. Spain: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 20. Spain: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 21. Spain: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 22. Rest of Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 23. Rest of Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 24. Rest of Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 25. Rest of Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 26. Recent Organic Growth Strategies in Gastrointestinal Drugs Market
  • Table 27. Recent Inorganic Growth Strategies in the Gastrointestinal Drugs Market
  • Table 28. Glossary of Terms, Gastrointestinal Drugs Market

List Of Figures

  • Figure 1. Europe Gastrointestinal Drugs Market Segmentation, by Country
  • Figure 2. Europe Gastrointestinal Drugs Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 5. Europe Gastrointestinal Drugs Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 6. Biologics: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Antidiarrheal and Laxatives: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Acid Neutralizers: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Anti-inflammatory Drugs: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Antiemetic and Antinauseants: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Others: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Europe Gastrointestinal Drugs Market Share (%) - by Application (2023 and 2031)
  • Figure 13. Irritable Bowel Syndrome: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Inflammatory Ulcerative Colitis: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Crohn's Disease: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Gastroenteritis: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Celiac Disease: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Others: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Europe Gastrointestinal Drugs Market Share (%) - by Route of Administration (2023 and 2031)
  • Figure 20. Oral: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Parenteral: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Europe Gastrointestinal Drugs Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 23. Hospital Pharmacies: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Retail Pharmacies: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Online Pharmacies: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Europe Gastrointestinal Drugs Market Breakdown, by Key Countries - Revenue (2023) (US$ Million)
  • Figure 27. Europe Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 28. Germany: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 29. United Kingdom: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. France: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Italy: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Spain: Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Rest of Europe Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Growth Strategies in Gastrointestinal Drugs Market